Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

CUSIP: 48576U106

Q3 2023 13F Holders as of 30 Sep 2023

Holder snapshot 7 signals
Share change
-5,430,574
Put/Call ratio
29%
SEC-reported price per share
$1.34
Number of holders
117
Value change
-$10,719,386
Number of buys
55
Open additional details 1 more signal available
Number of sells
62
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
22,658,403

Security key

48576U106

Report period

Q3 2023

Institutions

117

Top holders

10

Ownership snapshot

Top reported holders of KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock Finance, Inc.
Disclosed value leader
BlackRock Finance, Inc.
Comparable rows
0/15
Latest evidence
30 Jun 2023
13F Highest disclosed value: $20,651,735 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

BlackRock Finance, Inc. has the largest disclosed position value at $20.65M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock Finance, Inc.'s linked filing trail.
Disclosed position value Top 5
BlackRock Finance, Inc. $20.65M
VANGUARD GROUP INC $15.54M
Avidity Partners Management LP $14.98M
Palo Alto Investors LP $10.16M
CITADEL ADVISORS LLC $5.64M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$20,651,735
11,537,281 shares
— 30 Jun 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$15,544,589
8,684,128 shares
— 30 Jun 2023
Avidity Partners Management LP
13F
Company
13F
—
denominator unverified
$14,982,479
8,370,100 shares
— 30 Jun 2023
Palo Alto Investors LP
13F
Company
13F
—
denominator unverified
$10,159,818
5,675,876 shares
— 30 Jun 2023
CITADEL ADVISORS LLC
13F
Company
13F
—
denominator unverified
$5,637,931
3,149,682 shares
— 30 Jun 2023
MARSHALL WACE, LLP
13F
Company
13F
—
denominator unverified
$4,374,755
2,443,997 shares
— 30 Jun 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
117
Shares
76,219,647
Rows available
117
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q1 2026 Across Filers

Q1 2026 holders
1
Q3 2023 holders
117
Holder diff
116
Investor Q1 2026 Shares Q3 2023 Shares Share Diff Share Chg % Q1 2026 value Q3 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .